Cypherpunk Appoints Zcash CEO as Strategic Advisor to Enhance Privacy Tech
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Source: Newsfilter
- Strategic Advisor Appointment: Cypherpunk Technologies Inc. has appointed Josh Swihart, CEO of Electric Coin Company, as a Strategic Advisor, aiming to leverage his expertise to strengthen the Zcash ecosystem and drive long-term development of privacy technologies, reflecting the company's strong commitment to enhancing privacy solutions.
- Capital Injection: Following a $58.88 million private placement, Cypherpunk has deployed approximately $68 million to acquire 233,644.56 ZEC, representing about 1.43% of the total Zcash network supply, which will bolster its market position in the digital asset space.
- Leadership Expansion: With the addition of Zcash founder Zooko Wilcox, Cypherpunk's leadership team has been further strengthened, enhancing the company's governance structure and laying the groundwork for future innovations, indicating the company's ambitions in the privacy tech sector.
- Market Opportunity: By implementing a Zcash-focused digital asset strategy, Cypherpunk aims to capitalize on the growing importance of privacy technologies, emphasizing that privacy is foundational to freedom, thereby driving long-term value creation in the rapidly evolving digital asset market.
Analyst Views on CYPH
About CYPH
Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
